AMLX as reported
Amylyx Pharmaceuticals, Inc. reported $0 of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied
- Net Income
- −$150M
Net Income · −31% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$123M
Free Cash Flow · trailing twelve months to Q4 2025
- EPS
- −$1.48
EPS · −52% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2025 |
| Net Income | −$150M | −31% | Q1 2026 |
| EPS | −$1.48 | −52% | Q1 2026 |
| Gross Margin | 92% | n/a | Q3 2023 · 10 quarters behind |
| Op Margin | −42% | n/a | Q3 2023 · 10 quarters behind |
| Net Margin | −38% | n/a | Q3 2023 · 10 quarters behind |
| ROE | −65% | n/a | Q1 2026 |
| ROA | −58% | n/a | Q1 2026 |
| Free Cash Flow | −$123M | n/a | Q4 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Amylyx Pharmaceuticals, Inc. (AMLX) - Revenue & ProfitRevenue & ProfitAmylyx Pharmaceuticals, Inc. (AMLX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #3 of 28 by Smart Score